Head and Neck Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In March 2025, Coordination Pharmaceuticals Inc. announced a phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or ...
Advanced Cervical Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...
Medscape7h
SGO 2025: The Impact of Advancements in Individualized Therapies for Endometrial Cancer
Dr Kathleen Moore emphasizes the need for a more nuanced approach to endometrial cancer treatment, particularly in the ...
TMCnet8h
GSK Deadline: Rosen Law Firm Urges GSK plc (NYSE: GSK) Investors with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that GSK plc (NYSE: GSK) Misled ...
pharmaphorum10h
BeiGene abandons TIGIT antibody after lung cancer flop
TIGIT in particular has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months ...
GSK Investors Have Opportunity to Lead GSK plc Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Le Lézard14h
Shareholders that lost money on GSK plc(GSK) should contact The Gross Law Firm about pending Class Action - GSK
The Gross Law Firm issues the following notice to shareholders of GSK plc . Shareholders who purchased shares of GSK during the ...